本帖最后由 老马 于 2012-1-13 21:20 编辑
- v9 v- V& H# s3 p5 [6 l3 t* ]/ s- _! j( C4 V
爱必妥和阿瓦斯丁的比较0 ~9 K( u8 g; k$ d
1 ?9 ^" C. M* H, ^http://cancergrace.org/lung/2008/08/30/bms099-os-neg/+ a% n! b- `4 Q8 Z) K u
- I: y+ o# `, V1 ]3 H% \8 N
/ x0 v; d, W4 O8 mhttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
& p3 q- V/ _( {6 T" X( \) V==================================================* @, m [) D/ O7 q+ A$ D$ s
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
; s! f2 Y& B7 K9 g7 z7 O3 v/ _, u! KPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
1 V" e4 C0 g8 X: F' {Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.2 R0 @# U4 F, ?! h) G
|